Skip to main content

Table 1 Baseline characteristics of mCRC cases

From: Dickkopf-related protein 1, a new biomarker for local immune status and poor prognosis among patients with colorectal liver Oligometastases: a retrospective study

 DKK1 low serum level (%)DKK1 high serum level (%)P
Total2837 
Gender  0.683
 Male16 (57.1)23 (62.2) 
 Female12 (42.9)14 (37.8) 
Median age, range56, 32~7559, 30~760.454
Splenic flexure (primary tumor)  0.271
 Proximal5 (17.9)11 (29.7) 
 Distal23 (82.1)26 (70.3) 
Pathological determination  0.211
 Adenocarcinoma, NOS28 (100.0)35 (94.6) 
 Mucous adenocarcinoma0 (0.0)2 (5.4) 
R0 resection  0.278
 Yes27 (96.4)33 (89.2) 
 No1 (3.6)4 (10.8) 
Interventional therapy  0.773
 Yes26 (92.9)35 (94.6) 
 No2 (7.1)2 (5.4) 
Preoperative chemotherapy  0.190
 Yes7 (25.0)15 (40.5) 
 No21 (75.0)22 (59.5) 
Regimen of preoperative chemotherapy
 XELOX28 
 FOLFOX25 
 FOLFIRI32 
Postoperative chemotherapy  0.046
 Yes12 (42.9)25 (67.6) 
 No16 (57.1)12 (32.4) 
Regimen of postoperative chemotherapy
 XELODA01 
 XELOX911 
 FOLFOX17 
 FOLFIRI14 
 XELOX+XELODA12 
Preoperative CEA level (ng/L)  0.211
  ≤ 20028 (100.0)35 (94.6) 
  > 2000 (0.0)2 (5.4) 
Primary tumor node  0.058
 Positive10 (35.7)22 (59.5) 
 Negative18 (64.3)15 (40.5) 
Disease-free interval  0.161
  < 12 months25 (89.3)28 (75.7) 
  ≥ 12 months3 (10.7)9 (24.3) 
Tumor size  0.043
  ≤ 5 cm28 (100.0)32 (86.5) 
  > 5 cm0 (0.0)5 (13.5) 
CRS  0.347
 03 (10.7)2 (5.4) 
 115 (53.6)15 (40.5) 
 210 (35.7)18 (48.6) 
 30 (0)2 (5.4) 
  1. a mCRC, metastatic colorectal cancer; NOS, not otherwise specified; CRS, clinical risk score